2020
B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635)
Bar-Or A, Bennett J, Von Budingen H, Carruthers R, Edwards K, Fallis R, Fiore D, Gelfand J, Giacomini P, Greenberg B, Hafler D, Longbrake E, Assman B, Ionete C, Kaunzner U, Lock C, Ma X, Musch B, Pardo G, Pei J, Piehl F, Weber M, Ziemssen T, Herman A, Harp C, Cross A. B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1635.Peer-Reviewed Original Research
2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization
Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers In Immunology 2018, 8: 1844. PMID: 29379498, PMCID: PMC5775516, DOI: 10.3389/fimmu.2017.01844.Peer-Reviewed Original ResearchAntigen-presenting cellsRegulatory cellsTolerogenic antigen-presenting cellsT regulatory (Treg) cellsClinical applicationPosttransplant complicationsTreg preparationsAllergic diseasesClinical trialsTregsEfficacious treatmentTreg productsCellular therapyStandardized reportingMedicinal productsDifferent preparationsCellsInvestigatorsCD4ComplicationsTherapyDiseaseTrials
2007
Cytokines and interventional immunology
Hafler D. Cytokines and interventional immunology. Nature Reviews Immunology 2007, 7: 423-423. DOI: 10.1038/nri2101.Peer-Reviewed Original Research
1996
Three‐year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial
HOHOL M, KHOURY S, COOK S, ORAV E, HAFLER D, WEINER H. Three‐year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial. Annals Of The New York Academy Of Sciences 1996, 778: 243-250. PMID: 8610977, DOI: 10.1111/j.1749-6632.1996.tb21132.x.Peer-Reviewed Original Research